诚信认证:
工商注册信息已核实!
快速导航
产品分类
微信二维码
Minisite
血管生成
Bosutinib (SKI-606)
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
阿拉丁 | 生产商 | 上海 | 现货 |
产品参数
货号 | CAS号 | 操作 |
---|---|---|
B129905-50mg | 380843-75-4 | 询价 |
B129905-100mg | 380843-75-4 | 询价 |
B129905-10mg | 380843-75-4 | 询价 |
产品介绍
- 分子式 C26H29Cl2N5O3
- 分子量530.45
属性
溶解性 | Soluble in methanol, DMSO (≥15 mg/ml), and ethanol (25 mM). Very poorly soluble in water. Maximum solubility in plain water is estimated to be about 10-50 μM. Buffers, serum, or other additives may increase or decrease the aqueous solubility. |
描述
应用 | A c-Abl, Src-Abl, and Bcr-Abl inhibitor |
产品介绍 | Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase activity in CD34+ CML cells more potently than Imatinib. Activity of Src-Abl has been implicated in the development of other non-CML malignancies, and Bosutinib has demonstrated in studies to suppress breast cancer growth and migration. |
合法信息 | Sold for research purposes under agreement from Pfizer Inc. - Not for human or veterinary use. |
备注 | Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively. |
生化机理 | Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.Bosutinib (SKI-606) is an orally active; dual Src/Abl tyrosine kinase inhibitor with potent antiproliferative activity. It does not appear to inhibit c-Kit and PDGRF, which are thought to be the cause of numerous side effects in anticancer treatment with some other tyrosine kinase inhibitors. |
别名 | 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;SKI-606;WAY-173606;伯舒替尼;SKI-606;WAY-173606 |
Bosutinib (SKI-606)信息由上海阿拉丁生化科技股份有限公司为您提供,如您想了解更多关于Bosutinib (SKI-606)报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途